Recursion’s Phase 3 trial of REC-4881 in familial adenomatous polyposis will count removal of adenomas 10 mm or larger as events under an FDA-agreed design.
Recursion’s AI-selected MEK drug cuts FAP polyp burden in small trial
Recursion Pharmaceuticals dropped phase 1b/2 results Monday for REC-4881, a MEK inhibitor it flagged through AI screens. In 12 older patients (55 years old and older) with familial adenomatous polyposis, the drug trimmed total polyp burden a median 43% after three months. The gains stuck around: 12 weeks off treatment, the median drop climbed to…
